Market Cap 1.63B
Revenue (ttm) 263.50M
Net Income (ttm) -390.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -148.38%
Debt to Equity Ratio 0.00
Volume 9,747,399
Avg Vol 15,936,689
Day's Range N/A - N/A
Shares Out 411.96M
Stochastic %K 16%
Beta 0.69
Analysts Strong Sell
Price Target $8.36

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an int...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
Fosco_
Fosco_ Mar. 18 at 9:03 AM
$IMMX $IOVA $TGTX $AVDL Congratulations guys for AVDL Buy Out, IOVA long awaited Inflexion and TGTX overall success story, all conviction stocks I own or used to own from a lower price basis. Above all congratulations to the happy readers of my analysis on $IMMX who followed what seems now a no brainer !
0 · Reply
DeskPlatformModern
DeskPlatformModern Mar. 18 at 9:02 AM
$IOVA is on my radar in biotech, just observing.
0 · Reply
marti837
marti837 Mar. 18 at 7:34 AM
$IOVA Will they ever become profitable?
1 · Reply
RexColbrook
RexColbrook Mar. 18 at 7:21 AM
$IOVA IOVA just kinda sitting there… volume slowly creeping in range getting tighter meanwhile some people getting real loud on the bear side 🤡 not much noise on price though… interesting
1 · Reply
yammyYo
yammyYo Mar. 18 at 7:03 AM
$IOVA Yeah, I bought $100K at $5 and panic sold at $4.50 just to go full port on shorts. What of it?
1 · Reply
JM9190
JM9190 Mar. 18 at 6:54 AM
$IOVA AI tells me: As of March 17, 2026, the "big money" is heavily concentrated on the upside for the April 2, 2026 expiration. The open interest (OI) distribution shows that institutional traders are positioning for a breakout above current levels, specifically targeting the $5.00 and $6.00 marks. Bullish Skew: The massive disparity between Call OI at $5.00 and Put OI at $3.50 indicates that institutional sentiment is roughly 8:1 bullish for this specific expiration week. Resistance Levels: The stock faces significant technical resistance at $5.81 and $6.53. A break above these levels, fueled by high call volume, would likely trigger additional "buy" signals from automated trading systems. Unusual Activity: Traders recently bought nearly 28,000 call options in a single session—roughly 364% above the daily average—confirming that large players are aggressively front-running the March 31 deadline.
0 · Reply
yammyYo
yammyYo Mar. 18 at 6:02 AM
$IOVA my pisition is. Short now
1 · Reply
yammyYo
yammyYo Mar. 18 at 5:28 AM
$IOVA Just offering a different perspective here. The stock market is a cold-blooded game
0 · Reply
LostChang3
LostChang3 Mar. 18 at 4:54 AM
$IOVA since our new bear worships at the altar of AI Slop, i'll reply in their native language
1 · Reply
yammyYo
yammyYo Mar. 18 at 4:52 AM
$IOVA Does using AI change the facts? Attack the argument, not the person. Resorting to ad hominem just shows you have no real comeback
0 · Reply
Latest News on IOVA
What's Going On With Iovance Biotherapeutics Stock On Friday?

Mar 6, 2026, 1:06 PM EST - 11 days ago

What's Going On With Iovance Biotherapeutics Stock On Friday?


Iovance Biotherapeutics to Present at Upcoming Conferences

Feb 26, 2026, 8:00 AM EST - 19 days ago

Iovance Biotherapeutics to Present at Upcoming Conferences


Iovance Biotherapeutics: Bright Prospects For 2026

Dec 29, 2025, 12:51 AM EST - 2 months ago

Iovance Biotherapeutics: Bright Prospects For 2026


Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 8 months ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.


Fosco_
Fosco_ Mar. 18 at 9:03 AM
$IMMX $IOVA $TGTX $AVDL Congratulations guys for AVDL Buy Out, IOVA long awaited Inflexion and TGTX overall success story, all conviction stocks I own or used to own from a lower price basis. Above all congratulations to the happy readers of my analysis on $IMMX who followed what seems now a no brainer !
0 · Reply
DeskPlatformModern
DeskPlatformModern Mar. 18 at 9:02 AM
$IOVA is on my radar in biotech, just observing.
0 · Reply
marti837
marti837 Mar. 18 at 7:34 AM
$IOVA Will they ever become profitable?
1 · Reply
RexColbrook
RexColbrook Mar. 18 at 7:21 AM
$IOVA IOVA just kinda sitting there… volume slowly creeping in range getting tighter meanwhile some people getting real loud on the bear side 🤡 not much noise on price though… interesting
1 · Reply
yammyYo
yammyYo Mar. 18 at 7:03 AM
$IOVA Yeah, I bought $100K at $5 and panic sold at $4.50 just to go full port on shorts. What of it?
1 · Reply
JM9190
JM9190 Mar. 18 at 6:54 AM
$IOVA AI tells me: As of March 17, 2026, the "big money" is heavily concentrated on the upside for the April 2, 2026 expiration. The open interest (OI) distribution shows that institutional traders are positioning for a breakout above current levels, specifically targeting the $5.00 and $6.00 marks. Bullish Skew: The massive disparity between Call OI at $5.00 and Put OI at $3.50 indicates that institutional sentiment is roughly 8:1 bullish for this specific expiration week. Resistance Levels: The stock faces significant technical resistance at $5.81 and $6.53. A break above these levels, fueled by high call volume, would likely trigger additional "buy" signals from automated trading systems. Unusual Activity: Traders recently bought nearly 28,000 call options in a single session—roughly 364% above the daily average—confirming that large players are aggressively front-running the March 31 deadline.
0 · Reply
yammyYo
yammyYo Mar. 18 at 6:02 AM
$IOVA my pisition is. Short now
1 · Reply
yammyYo
yammyYo Mar. 18 at 5:28 AM
$IOVA Just offering a different perspective here. The stock market is a cold-blooded game
0 · Reply
LostChang3
LostChang3 Mar. 18 at 4:54 AM
$IOVA since our new bear worships at the altar of AI Slop, i'll reply in their native language
1 · Reply
yammyYo
yammyYo Mar. 18 at 4:52 AM
$IOVA Does using AI change the facts? Attack the argument, not the person. Resorting to ad hominem just shows you have no real comeback
0 · Reply
LostChang3
LostChang3 Mar. 18 at 4:41 AM
$IOVA yammyYO is one AI-slop of a bear. Details below. Check the replies for more
4 · Reply
yammyYo
yammyYo Mar. 18 at 4:40 AM
0 · Reply
yammyYo
yammyYo Mar. 18 at 4:37 AM
$IOVA Stop the blind optimism and face the facts. That 37% short interest isn’t there because they’re stupid—it’s there because the cold, hard reality is hitting
1 · Reply
yammyYo
yammyYo Mar. 18 at 4:34 AM
$IOVA REALITY OF IOVA 1. One-Trick Pony Stop the hype. $IOVA is stuck in a niche melanoma sandbox. '25 growth was just launch-day luck. Once they hit the market ceiling in '26, there’s nowhere to go. They’re a single-indication play, not a giant 2. NSCLC is a Different Beast Lung cancer isn't melanoma. It's a much tougher environment. Thinking TILs will 'just work' in NSCLC is a rookie mistake. One clinical miss and this stock craters to zero 3. The Preconditioning Trap TAM is a lie. TIL therapy requires brutal chemo to 'nuke' the immune system. Most late-stage patients are too frail to survive the prep. The actual eligible pool is a fraction of what bulls claim 4. Margin & Cash Burn 22-day bespoke manufacturing is a logistical nightmare. COGS will stay sky-high. They’re burning cash faster than they can grow. Expect more dilution before they ever see a profit. 5. Massive Execution Risk Scaling a toxic treatment is nearly impossible.
1 · Reply
yammyYo
yammyYo Mar. 18 at 4:29 AM
$IOVA This thread is a total echo chamber. Everyone’s blinded by the hype and completely ignoring the risks. Sure, revenue grew quarter-over-quarter in '25, but that doesn't guarantee a repeat in '26. Let's be real: they’re a one-trick pony right now. Melanoma is a niche market with a hard ceiling. Without more FDA approvals, it’s just a single-indication play. Lung cancer (NSCLC) is a whole different beast compared to melanoma. Plus, people keep confusing 'total addressable patients' with actual sales. These patients have to undergo brutal lymphodepletion—how many late-stage, fragile patients can actually survive that process? Equating the entire patient pool to the market size is pure delusion
1 · Reply
yammyYo
yammyYo Mar. 18 at 4:23 AM
$IOVA If we don't bounce today, the technicals are toast
0 · Reply
Jay_Bingo
Jay_Bingo Mar. 18 at 3:37 AM
$IOVA Could go to 3.6 before bounce. Market is very choppy, no direction. Dump's irrational and clueless governance is a big drag on the market.
1 · Reply
katanare
katanare Mar. 18 at 12:55 AM
$IOVA Trading at $4$6 and that doesn’t match what’s already there. — Revenue growing — Margins improving — Approved product — Real pipeline upside $10 is easily justified with basic execution $12$15 is serious territory $20+ is in play if NSCLC hits and the market reprices Calling $8 a ceiling makes no sense This isn’t just hype anymore, there are real sales and real science Anyone selling here is giving up value too early
2 · Reply
Don_Heisenberg
Don_Heisenberg Mar. 18 at 12:53 AM
$IOVA ignore the kindergarten chart "analysis". The RSI bullish divergance on the 1h chart is based on data that actually exists. Call it considation.
3 · Reply
kaoz
kaoz Mar. 18 at 12:33 AM
$IOVA wild after hours
1 · Reply
profits7
profits7 Mar. 18 at 12:31 AM
0 · Reply
Yaheldav
Yaheldav Mar. 18 at 12:29 AM
$IOVA when an insituation buys two days ago shares worth 2 million dollars, you jusg follow the money
0 · Reply